{"name":"Pharming Technologies B.V.","slug":"pharming-technologies-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"recombinant human C1 inhibitor","genericName":"recombinant human C1 inhibitor","slug":"recombinant-human-c1-inhibitor","indication":"Hereditary angioedema","status":"phase_3"}]}],"pipeline":[{"name":"recombinant human C1 inhibitor","genericName":"recombinant human C1 inhibitor","slug":"recombinant-human-c1-inhibitor","phase":"phase_3","mechanism":"Recombinant human C1 inhibitor works by replacing a deficient or dysfunctional C1 inhibitor protein to regulate the complement system and prevent excessive inflammation.","indications":["Hereditary angioedema"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQaF9YZzNrbUZaT21uazUwVHFmOWdSNFg1YnlUMVpkejhwRnpkaGtMdzIxb1pTbWN2SENxR3daOUZBc2ItaVZyZFJuR0dqeWxVOHVvRjhXRW9KS1R6WmlLUEdqZHVSaURwY2E0VEswbENSQWNhUmFKOW1jMEdYd2F2V1pZMUJKRHBVSlJuc2FJaDR3dGEwcWVKYmk0SWlna054Ry1BS3BrNzk2U2owOEhPM3FtSQ?oc=5","date":"2026-03-27","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026 - European Medicines ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWFJxdS10Ynh3d3lFU0dYV204ZVFtdTMxU01GQU10T2lpTzR1a3hocDNrNlo4M2hjM2lIOEV5UnZPbjlyOUZ4RUFxYnM0RDV3U3J5VlZKaFMtUzRaLWtsaFZBSnlvYlUwMC1xeHhvb2l3anZrdmJobWd3SVlURGJEQi14di1UT3BWSDdV?oc=5","date":"2025-02-07","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period - Yahoo Finance UK","headline":"Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQLW5OSnk2THlQYkZ4X09nZEdsZG94cWZvT1dWWVh2UUtRcDU0QTdwbzQyZFBtb1pRMnd1ZnJCSUZZckRSTUZROFN5Wk84OHljbE5Da250ZERscGxmckhOcTZsQXM2RVpwOUlVQzYteHhocFQtTUxmY08xcm5vMnVvQllMX0ZVZHA5R2ZPdjdDd1NYcUZDc0ZLNnI3V3hlOFZiTzhaVi1nR0E0aENLTDhSZ0RyS0M?oc=5","date":"2024-12-16","type":"pipeline","source":"Fierce Biotech","summary":"Pharming pays $66M for Abliva and its 'blockbuster potential' mitochondrial disease med - Fierce Biotech","headline":"Pharming pays $66M for Abliva and its 'blockbuster potential' mitochondrial disease med","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQMHppSXd2RXNPOVdMN0Y2MndpNUk1SjFqTEFxSFVqanh4aEdRUzlpNzdra3RDS2kxT0hXRFhJMmNMUU5oR1ZWeGprUU9ZVjdCNGJFcmRXZXh0bWtGaF9Oc3d4MzgtcEV0RnRXdFIxUXU2RTByVTVzcWZ6SGtNNTdfS2xDYVBxUF82WGxFQ3dwSlhiNVZLcWNTVGJWNUxxc0hpUllVY3JaRmRjeXhUcTRVUlg0Z0l5MnBUUlY4OEN0TEdpVmhoei0wdF9Lc1JCVEQ2MFBPZDRZRG4?oc=5","date":"2024-12-15","type":"pipeline","source":"GlobeNewswire","summary":"Pharming announces public cash offer to the shareholders of Abliva AB - GlobeNewswire","headline":"Pharming announces public cash offer to the shareholders of Abliva AB","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}